# Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer

> **NCT00653250** · NA · COMPLETED · sponsor: **Vanderbilt-Ingram Cancer Center** · enrollment: 22 (actual)

## Conditions studied

- Lung Cancer

## Interventions

- **DRUG:** celecoxib
- **PROCEDURE:** biopsy
- **PROCEDURE:** therapeutic conventional surgery

## Key facts

- **NCT ID:** NCT00653250
- **Lead sponsor:** Vanderbilt-Ingram Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-12
- **Primary completion:** 2006-03
- **Final completion:** 2008-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2013-05-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00653250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00653250, "Celecoxib in Treating Patients With Stage I, Stage II, or Stage IIIA Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00653250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*